Jennifer Brigitte Green

Journal Article Metabolism · October 2024 The spectrum of cardiorenal and metabolic diseases comprises many disorders, including obesity, type 2 diabetes (T2D), chronic kidney disease (CKD), atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), dyslipidemias, hypertension, and associ ... Full text Link to item Cite

The Final Frontier in Diabetes Care: Implementing Research in Real-World Practice.

Journal Article Diabetes Care · August 1, 2024 Despite extensive evidence related to the prevention and management of type 2 diabetes (T2D) and its complications, most people at risk for and people who have diabetes do not receive recommended guideline-based care. Clinical implementation of proven care ... Full text Link to item Cite

Effects of albiglutide on myocardial infarction and ischaemic heart disease outcomes in patients with type 2 diabetes and cardiovascular disease in the Harmony Outcomes trial.

Journal Article Eur Heart J Cardiovasc Pharmacother · July 16, 2024 AIMS: Large outcome trials have demonstrated cardiovascular benefits of selected glucagon-like peptide-1 (GLP-1) receptor agonists. We examined coronary disease outcomes in the Harmony Outcomes trial of the GLP-1 receptor agonist albiglutide. METHODS AND R ... Full text Link to item Cite

Effects of an Intervention to Improve Evidence-Based Care for People With Diabetes and Cardiovascular Disease Across Sex, Race, and Ethnicity Subgroups: Insights From the COORDINATE-Diabetes Trial.

Journal Article Circulation · July 16, 2024 BACKGROUND: Results from the COORDINATE-Diabetes trial (Coordinating Cardiology Clinics Randomized Trial of Interventions to Improve Outcomes - Diabetes) demonstrated that a multifaceted, clinic-based intervention increased prescription of evidence-based m ... Full text Link to item Cite

Impact of empagliflozin on insulin needs in patients with heart failure and diabetes: An EMPEROR-Pooled analysis.

Journal Article Diabetes Obes Metab · July 2024 AIM: To assess the effect of empagliflozin on patients with comorbid heart failure (HF) and diabetes with or without baseline insulin, and to study the impact of empagliflozin on insulin requirements over time. MATERIALS AND METHODS: We performed a post-ho ... Full text Link to item Cite

Effect of albiglutide on cardiovascular outcomes in older adults: A post hoc analysis of a randomized controlled trial.

Journal Article Diabetes Obes Metab · May 2024 AIM: To analyse the effects of albiglutide, a glucagon-like peptide 1 receptor agonist, on cardiovascular outcomes in older adults aged ≥65 years with type 2 diabetes and cardiovascular disease who participated in the Harmony Outcomes trial (NCT02465515). ... Full text Link to item Cite

Disparities in prevalence and treatment of diabetes, cardiovascular and chronic kidney diseases - Recommendations from the taskforce of the guideline workshop.

Journal Article Diabetes Res Clin Pract · May 2024 There is a mounting clinical, psychosocial, and socioeconomic burden worldwide as the prevalence of diabetes, cardiovascular disease (CVD), and chronic kidney disease (CKD) continues to rise. Despite the introduction of therapeutic interventions with demon ... Full text Link to item Cite

Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study).

Journal Article Circulation · March 26, 2024 BACKGROUND: Cardiovascular disease is a major cause of morbidity and mortality in patients with type 2 diabetes. The effects of glucose-lowering medications on cardiovascular outcomes in individuals with type 2 diabetes and low cardiovascular risk are uncl ... Full text Link to item Cite

Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD.

Journal Article J Am Soc Nephrol · February 1, 2024 SIGNIFICANCE STATEMENT: SGLT2 inhibitors reduce risk of kidney progression, AKI, and cardiovascular disease, but the mechanisms of benefit are incompletely understood. Bioimpedance spectroscopy can estimate body water and fat mass. One quarter of the EMPA- ... Full text Link to item Cite

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.

Journal Article Lancet Diabetes Endocrinol · January 2024 BACKGROUND: Sodium-glucose co-transporter-2 (SGLT2) inhibitors reduce progression of chronic kidney disease and the risk of cardiovascular morbidity and mortality in a wide range of patients. However, their effects on kidney disease progression in some pat ... Full text Link to item Cite

Reflecting on a Year at the Helm of Diabetes Care.

Journal Article Diabetes Care · January 1, 2024 Full text Link to item Cite

"The price is right" for diabetes management of older adults - Evidence for the closest glycemic target without going over.

Journal Article J Am Geriatr Soc · December 2023 Full text Link to item Cite

The Role of Ultra-Rapid-Acting Insulin Analogs in Diabetes: An Expert Consensus.

Journal Article J Diabetes Sci Technol · November 8, 2023 Ultra-rapid-acting insulin analogs (URAA) are a further development and refinement of rapid-acting insulin analogs. Because of their adapted formulation, URAA provide an even faster pharmacokinetics and thus an accelerated onset of insulin action than conv ... Full text Link to item Cite

Guideline Development for Medical Device Technology: Issues for Consideration.

Journal Article J Diabetes Sci Technol · November 2023 Advances in the development of innovative medical devices and telehealth technologies create the potential to improve the quality and efficiency of diabetes care through collecting, aggregating, and interpreting relevant health data in ways that facilitate ... Full text Link to item Cite

Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline workshop.

Journal Article Cardiovasc Diabetol · October 13, 2023 In recent years, several novel agents have become available to treat individuals with type 2 diabetes (T2D), such as sodium-glucose cotransporter-2 inhibitors (SGLT-2i), tirzepatide, which is a dual glucose-dependent insulinotropic polypeptide receptor ago ... Full text Link to item Cite

The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone: Post hoc analysis of the FIDELITY study.

Journal Article Diabetes Obes Metab · October 2023 AIM: To assess the effect of finerenone on the risk of cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes, with and without obesity. MATERIALS AND METHODS: A post hoc analysis of the prespecified pooled FIDELITY ... Full text Link to item Cite

Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes.

Journal Article JCI Insight · September 8, 2023 Metabolic mechanisms underlying the heterogeneity of major adverse cardiovascular (CV) event (MACE) risk in individuals with type 2 diabetes mellitus (T2D) remain unclear. We hypothesized that circulating metabolites reflecting mitochondrial dysfunction pr ... Full text Link to item Cite

GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes.

Journal Article J Am Coll Cardiol · August 8, 2023 BACKGROUND: Sodium-glucose cotransporter-2 (SGLT2) inhibitors and GLP-1 receptor agonists (GLP-1 RAs) reduce adverse cardiovascular outcomes in type 2 diabetes (T2D). However, the efficacy of combination therapy is unclear. OBJECTIVES: The aim of this stud ... Full text Link to item Cite

Sex differences in the complications, care and clinical outcomes of patients with type 2 diabetes in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).

Journal Article Diabetes Obes Metab · June 2023 AIM: To examine sex differences in the characteristics and outcomes in participants with type 2 diabetes (T2D), with or without cardiovascular disease (CVD), randomized to once-weekly exenatide (EQW) or placebo in the Exenatide Study of Cardiovascular Even ... Full text Link to item Cite

Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes: A Randomized Clinical Trial.

Journal Article JAMA · April 18, 2023 IMPORTANCE: Evidence-based therapies to reduce atherosclerotic cardiovascular disease risk in adults with type 2 diabetes are underused in clinical practice. OBJECTIVE: To assess the effect of a coordinated, multifaceted intervention of assessment, educati ... Full text Link to item Cite

DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases.

The Final Frontier in Diabetes Care: Implementing Research in Real-World Practice.

Effects of albiglutide on myocardial infarction and ischaemic heart disease outcomes in patients with type 2 diabetes and cardiovascular disease in the Harmony Outcomes trial.

Effects of an Intervention to Improve Evidence-Based Care for People With Diabetes and Cardiovascular Disease Across Sex, Race, and Ethnicity Subgroups: Insights From the COORDINATE-Diabetes Trial.

Impact of empagliflozin on insulin needs in patients with heart failure and diabetes: An EMPEROR-Pooled analysis.

Effect of albiglutide on cardiovascular outcomes in older adults: A post hoc analysis of a randomized controlled trial.

Disparities in prevalence and treatment of diabetes, cardiovascular and chronic kidney diseases - Recommendations from the taskforce of the guideline workshop.

Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study).

Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD.

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.

Reflecting on a Year at the Helm of Diabetes Care.

Journal Article Diabetes Care · January 1, 2024 Full text Link to item Cite

"The price is right" for diabetes management of older adults - Evidence for the closest glycemic target without going over.

Journal Article J Am Geriatr Soc · December 2023 Full text Link to item Cite

The Role of Ultra-Rapid-Acting Insulin Analogs in Diabetes: An Expert Consensus.

Guideline Development for Medical Device Technology: Issues for Consideration.

Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline workshop.

The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone: Post hoc analysis of the FIDELITY study.

Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes.

GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes.

Sex differences in the complications, care and clinical outcomes of patients with type 2 diabetes in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).

Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes: A Randomized Clinical Trial.

Higher burden of cardiometabolic and socioeconomic risk factors in women with type 2 diabetes: an analysis of the Glycemic Reduction Approaches in Diabetes (GRADE) baseline cohort.

Journal Article BMJ open diabetes research & care · April 2023 IntroductionType 2 diabetes mellitus (T2DM) is a powerful risk factor for cardiovascular disease (CVD), conferring a greater relative risk in women than men. We sought to examine sex differences in cardiometabolic risk factors and management in th ... Full text Cite

Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE).

Journal Article Nephrol Dial Transplant · March 31, 2023 BACKGROUND: Despite available interventions, people with type 2 diabetes (T2D) remain at risk of chronic kidney disease (CKD). Finerenone, a potent and selective nonsteroidal mineralocorticoid receptor antagonist, and sodium-glucose cotransporter 2 inhibit ... Full text Link to item Cite

CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes.

Journal Article Cardiovasc Diabetol · March 16, 2023 The 8th Cardiovascular Outcome Trial (CVOT) Summit on Cardiovascular, Kidney, and Glycemic Outcomes was held virtually on November 10-12, 2022. Following the tradition of previous summits, this reference congress served as a platform for in-depth discussio ... Full text Link to item Cite

Coordinating Cardiology clinics randomized trial of interventions to improve outcomes (COORDINATE) - Diabetes: rationale and design.

Journal Article Am Heart J · February 2023 Several medications that are proven to reduce cardiovascular events exist for individuals with type 2 diabetes mellitus (T2DM) and atherosclerotic cardiovascular disease, however they are substantially underused in clinical practice. Clinician, patient, an ... Full text Link to item Cite

Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases.

Journal Article J Diabetes Complications · February 2023 Increasing rates of obesity and diabetes have driven corresponding increases in related cardiorenal and metabolic diseases. In many patients, these conditions occur together, further increasing morbidity and mortality risks to the individual. Yet all too o ... Full text Link to item Cite

Empagliflozin in Patients with Chronic Kidney Disease.

Journal Article N Engl J Med · January 12, 2023 BACKGROUND: The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of s ... Full text Link to item Cite

"The Times They Are A-Changin'" at Diabetes Care.

Journal Article Diabetes Care · January 1, 2023 Full text Link to item Cite

Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Journal Article Diabetologia · December 2022 The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycaemia in type 2 diabetes in adults, published since 2006 and last updated in ... Full text Link to item Cite

Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.

Journal Article Lancet · November 19, 2022 BACKGROUND: Large trials have shown that sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of adverse kidney and cardiovascular outcomes in patients with heart failure or chronic kidney disease, or with type 2 diabetes and high risk of ath ... Full text Link to item Cite

Improving outcomes in cardio-renal-metabolic diseases.

Journal Article J Card Fail · November 2022 Full text Link to item Cite

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Journal Article Diabetes Care · November 1, 2022 The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycemia in type 2 diabetes in adults, published since 2006 and last updated in ... Full text Link to item Cite

Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.

Journal Article N Engl J Med · September 22, 2022 BACKGROUND: Data are lacking on the comparative effectiveness of commonly used glucose-lowering medications, when added to metformin, with respect to microvascular and cardiovascular disease outcomes in persons with type 2 diabetes. METHODS: We assessed th ... Full text Link to item Cite

Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes.

Journal Article Circulation · August 30, 2022 BACKGROUND: Empagliflozin improves outcomes in patients with heart failure with a preserved ejection fraction, but whether the effects are consistent in patients with and without diabetes remains to be elucidated. METHODS: Patients with class II through IV ... Full text Link to item Cite

Development and validation of a model to predict cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease.

Journal Article Cardiovasc Diabetol · August 27, 2022 BACKGROUND: Among individuals with atherosclerotic cardiovascular disease (ASCVD), type 2 diabetes mellitus (T2DM) is common and confers increased risk for morbidity and mortality. Differentiating risk is key to optimize efficiency of treatment selection. ... Full text Link to item Cite

Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association.

Journal Article Diabetes Care · July 7, 2022 Heart failure (HF) has been recognized as a common complication of diabetes, with a prevalence of up to 22% in individuals with diabetes and increasing incidence rates. Data also suggest that HF may develop in individuals with diabetes even in the absence ... Full text Link to item Cite

Re-adjudication of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) with study-level meta-analysis of hospitalization for heart failure from cardiovascular outcomes trials with dipeptidyl peptidase-4 (DPP-4) inhibitors.

Journal Article Clin Cardiol · July 2022 BACKGROUND: Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) assessed the cardiovascular (CV) safety of sitagliptin versus placebo on CV outcomes in patients with type 2 diabetes and CV disease and found sitagliptin noninferior to placebo. ... Full text Link to item Cite

Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial.

Journal Article Nephrol Dial Transplant · June 23, 2022 BACKGROUND: The effects of the sodium-glucose co-transporter 2 inhibitor empagliflozin on renal and cardiovascular disease have not been tested in a dedicated population of people with chronic kidney disease (CKD). METHODS: The EMPA-KIDNEY trial is an inte ... Full text Link to item Cite

Validation of the WATCH-DM and TRS-HFDM Risk Scores to Predict the Risk of Incident Hospitalization for Heart Failure Among Adults With Type 2 Diabetes: A Multicohort Analysis.

Journal Article J Am Heart Assoc · June 7, 2022 Background The WATCH-DM (weight [body mass index], age, hypertension, creatinine, high-density lipoprotein cholesterol, diabetes control [fasting plasma glucose], ECG QRS duration, myocardial infarction, and coronary artery bypass grafting) and TRS-HFDM (T ... Full text Link to item Cite

Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: JACC Guideline Comparison.

Journal Article J Am Coll Cardiol · May 10, 2022 Cardiovascular disease is a leading cause of morbidity and mortality in individuals with type 2 diabetes mellitus. These high-risk patients benefit from aggressive risk factor management, with blood pressure and low-density lipoprotein-cholesterol treatmen ... Full text Link to item Cite

A survey of multidisciplinary healthcare providers utilizing the KNOWintegrativeoncology.org educational platform.

Journal Article BMC Complement Med Ther · April 28, 2022 BACKGROUND: Although the vast majority of cancer patients use natural health products (NHPs), 59% of oncology healthcare providers (HCP) report not receiving any education on NHPs. KNOWintegrativeoncology.org (KNOW) is a web-based educational platform that ... Full text Link to item Cite

Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With Heart Failure and Diabetes.

Journal Article JACC Heart Fail · March 2022 OBJECTIVES: The authors sought to characterize associations between initiation of metformin and sulfonylurea therapy and clinical outcomes among patients with comorbid heart failure (HF) and diabetes (overall and by ejection fraction [EF] phenotype). BACKG ... Full text Open Access Link to item Cite

DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases.

Journal Article J Diabetes Complications · February 2022 Type 2 diabetes (T2D), chronic kidney disease (CKD), atherosclerotic cardiovascular disease (ASCVD), and heart failure (HF)-along with their associated risk factors-have overlapping etiologies, and two or more of these conditions frequently occur in the sa ... Full text Link to item Cite

Use of Lipid-, Blood Pressure-, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.

Journal Article JAMA Netw Open · February 1, 2022 IMPORTANCE: Based on contemporary estimates in the US, evidence-based therapies for cardiovascular risk reduction are generally underused among patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD). OBJECTIVE: To determine the us ... Full text Link to item Cite

Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine.

Conference Diabetes Care · January 1, 2022 OBJECTIVE: Phenotypic heterogeneity among patients with type 2 diabetes mellitus (T2DM) and atherosclerotic cardiovascular disease (ASCVD) is ill defined. We used cluster analysis machine-learning algorithms to identify phenotypes among trial participants ... Full text Link to item Cite

Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial.

Journal Article Lancet Diabetes Endocrinol · January 2022 BACKGROUND: It is important to evaluate whether a new treatment for heart failure with reduced ejection fraction (HFrEF) provides additive benefit to background foundational treatments. As such, we aimed to evaluate the efficacy and safety of empagliflozin ... Full text Link to item Cite

Roles for SGLT2 Inhibitors in Cardiorenal Disease.

Journal Article Cardiorenal Med · 2022 INTRODUCTION: Cardiovascular (CV) disease and chronic kidney disease (CKD) share common risk factors, including type 2 diabetes mellitus (T2DM). In CV outcome studies of patients with T2DM, sodium-glucose cotransporter 2 inhibitor (SGLT2i) therapy was asso ... Full text Link to item Cite

Impact of empagliflozin on insulin use in patients with heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes: sub-analysis from EMPEROR-Preserved trial

Conference DIABETOLOGIA · 2022 Cite

The cross-sectional association of cognition with diabetic peripheral and autonomic neuropathy-The GRADE study.

Journal Article J Diabetes Complications · December 2021 BACKGROUND: Studies examining whether measures of cognition are related to the presence of diabetic peripheral neuropathy (DPN) and/or cardiovascular autonomic neuropathy (CAN) are lacking, as are data regarding factors potentially explaining such associat ... Full text Link to item Cite

In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction.

Journal Article J Am Coll Cardiol · November 16, 2021 Sodium-glucose cotransporter-2 inhibitor therapy is well suited for initiation during the heart failure hospitalization, owing to clinical benefits that accrue rapidly within days to weeks, a strong safety and tolerability profile, minimal to no effects on ... Full text Link to item Cite

Empagliflozin in Heart Failure with a Preserved Ejection Fraction.

Journal Article N Engl J Med · October 14, 2021 BACKGROUND: Sodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart failure and a preserved ejection fraction ar ... Full text Link to item Cite

Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community.

Journal Article Circulation · July 6, 2021 Multiple sodium glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) have been shown to impart significant cardiovascular and kidney benefits, but are underused in clinical practice. Both SGLT-2i and GLP-1RA ... Full text Link to item Cite

Towards living guidelines on cardiorenal outcomes in diabetes: A pilot project of the Taskforce of the Guideline Workshop 2020.

Journal Article Diabetes Res Clin Pract · July 2021 In June 2020, the Taskforce of the Guideline Workshop 2019 convened via teleconferencing to initiate a pilot project that demonstrates the various processes and considerations involved in developing high-quality, evidence-based clinical practice guidelines ... Full text Link to item Cite

Assessment of North American Clinical Research Site Performance During the Start-up of Large Cardiovascular Clinical Trials.

Journal Article JAMA Netw Open · July 1, 2021 IMPORTANCE: Randomized clinical trials (RCTs) are critical in advancing patient care, yet conducting such large-scale trials requires tremendous resources and coordination. Clinical site start-up performance metrics can provide insight into opportunities f ... Full text Link to item Cite

Cardiovascular Consequences of Gestational Diabetes.

Journal Article Circulation · March 9, 2021 Full text Link to item Cite

Gaps in Evidence-Based Therapy Use in Insured Patients in the United States With Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease.

Journal Article J Am Heart Assoc · January 19, 2021 Background Evidence-based therapies are generally underused for cardiovascular risk reduction; however, less is known about contemporary patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease. Methods and Results Pharmacy and med ... Full text Link to item Cite

Standards of medical care in diabetes - 2021 abridged for primary care providers

Journal Article Clinical Diabetes · January 1, 2021 Full text Cite

Novel Treatment Advances and Approaches in the Management of Type 2 Diabetes: A Closer Look at the Evolving Role of SGLT2 Inhibitors

Journal Article Journal of Managed Care Medicine · January 1, 2021 Although cardiovascular and kidney disease are well known complications of diabetes, the use of guideline-directed therapies which reduce these risks are seriously suboptimal. Increasing use of the diabetes medications, along with antihypertensives and lip ... Cite

Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial.

Journal Article Eur J Heart Fail · November 2020 AIMS: Whether glycaemic control is associated with cardiovascular outcomes in patients with type 2 diabetes (T2D) is unclear. Consequently, we assessed the relationship between glycated haemoglobin (HbA1c ) and cardiovascular outcomes in a placebo-controll ... Full text Link to item Cite

Prevalence of microvascular and macrovascular disease in the Glycemia Reduction Approaches in Diabetes - A Comparative Effectiveness (GRADE) Study cohort.

Journal Article Diabetes Res Clin Pract · July 2020 AIMS: The Glycemia Reduction Approaches in Diabetes - A Comparative Effectiveness (GRADE) trial is a randomized clinical trial comparing glycemic effects of four diabetes medications added to metformin in type 2 diabetes (T2D). Microvascular and macrovascu ... Full text Link to item Cite

Proceedings of the Guideline Workshop 2019: Strategies for the Optimization of Guideline Processes in Diabetes, Cardiovascular Diseases, and Kidney Diseases.

Journal Article Diabetes Technol Ther · July 2020 The Guideline Workshop 2019, held in October 2019 in Munich, Germany, had the purpose of facilitating discussion on strategies for optimization of guideline processes in diabetes among a group of representatives of renown national and international societi ... Full text Link to item Cite

Comparative Effectiveness of Primary Prevention Implantable Cardioverter-Defibrillators in Older Heart Failure Patients With Diabetes Mellitus.

Journal Article J Am Heart Assoc · June 16, 2020 Background There are conflicting data regarding the benefit of primary prevention implantable cardioverter-defibrillators (ICDs) in patients with diabetes mellitus and heart failure (HF) with reduced ejection fraction. We aimed to assess the comparative ef ... Full text Link to item Cite

Proceedings of the Guideline Workshop 2019 - Strategies for the optimization of guideline processes in diabetes, cardiovascular diseases and kidney diseases.

Journal Article Diabetes Res Clin Pract · April 2020 The Guideline Workshop 2019, held in October 2019 in Munich, Germany, had the purpose of facilitating discussion on strategies for optimization of guideline processes in diabetes amongst a group of representatives of renown national and international socie ... Full text Link to item Cite

Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions.

Journal Article Circulation · March 10, 2020 Responding to concerns about the potential for increased risk of adverse cardiovascular outcomes, specifically myocardial infarction, associated with certain glucose-lowering therapies, the US Food and Drug Administration and the Committee for Medicinal Pr ... Full text Link to item Cite

Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS.

Journal Article Am Heart J · February 2020 BACKGROUND: Type 2 diabetes (T2D) patients are at increased risk for cardiovascular (CV) events. Most guidelines recommend treating low-density lipoprotein cholesterol (LDL-C) levels to ≤70 mg/dL (1.8 mM) for patients with T2D and established atherosclerot ... Full text Link to item Cite

Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS.

Journal Article Am Heart J · January 2020 BACKGROUND: Obesity is a risk factor for type 2 diabetes (T2D) and cardiovascular disease (CVD). Whether obesity affects outcomes among those with T2D and atherosclerotic CVD (ASCVD) remains uncertain. Our objective was to investigate the relationship betw ... Full text Link to item Cite

Erratum: The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: A rationale for the EMPAKIDNEY study (Clinical Kidney Journal (2018) 11:6 (749-761) DOI: 10.1093/ckj/sfy090)

Journal Article Clinical Kidney Journal · January 1, 2020 In the footnote of Figure 5 “Empagliflozin 0/4687 vs placebo 1/2333 participant reported Fournier's gangrene (perineal necrotizing fasciitis)” has been replaced with “Empagliflozin 0/4687 vs placebo 0/2333 participants reported Fournier's gangrene (perinea ... Full text Cite

Rationale and Design for a GRADE Substudy of Continuous Glucose Monitoring.

Journal Article Diabetes Technol Ther · December 2019 Background: The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) study has enrolled a racially and ethnically diverse population with type 2 diabetes, performed extensive phenotyping, and randomly assigned the participants to ... Full text Link to item Cite

International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS.

Journal Article Am Heart J · December 2019 International differences in management/outcomes among patients with type 2 diabetes and heart failure (HF) are not well characterized. We sought to evaluate geographic variation in treatment and outcomes among these patients. METHODS AND RESULTS: Among 14 ... Full text Open Access Link to item Cite

Associations between β-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease.

Journal Article Am Heart J · December 2019 BACKGROUND: The effects of β-blocker therapy in patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease (ASCVD) are unclear. We sought to evaluate associations between β-blocker use in T2D with ASCVD and cardiovascular (C ... Full text Link to item Cite

Characteristics and Outcomes of Atrial Fibrillation in Patients With Thyroid Disease (from the ARISTOTLE Trial).

Journal Article Am J Cardiol · November 1, 2019 Whether patients with atrial fibrillation (AF) and thyroid disease are clinically distinct from those with AF and no thyroid disease is unknown. Furthermore, the effectiveness of anticoagulation for prevention of AF-related thromboembolic events in patient ... Full text Link to item Cite

BARI 2D: A Reanalysis Focusing on Cardiovascular Events.

Journal Article Mayo Clin Proc · November 2019 OBJECTIVE: To reanalyze the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial using a new composite cardiovascular disease (CVD) outcome to determine how best to treat patients with type 2 diabetes mellitus and stable coronary artery dise ... Full text Link to item Cite

Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.

Journal Article Eur J Heart Fail · October 2019 Drugs that inhibit the sodium-glucose co-transporter 2 (SGLT2) have been shown to reduce the risk of hospitalizations for heart failure in patients with type 2 diabetes. In populations that largely did not have heart failure at the time of enrolment, empag ... Full text Link to item Cite

Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.

Journal Article Eur J Heart Fail · October 2019 BACKGROUND: The principal biological processes that characterize heart failure with a preserved ejection fraction (HFpEF) are systemic inflammation, epicardial adipose tissue accumulation, coronary microcirculatory rarefaction, myocardial fibrosis and vasc ... Full text Link to item Cite

Atrial Fibrillation and Diabetes Mellitus: JACC Review Topic of the Week.

Journal Article J Am Coll Cardiol · August 27, 2019 Diabetes mellitus is one of the most common chronic medical conditions, and is a risk factor for the development of atrial fibrillation (AF). The presence of diabetes in patients with AF is associated with increased symptom burden and increased cardiovascu ... Full text Link to item Cite

Antithrombotic treatment gap among patients with atrial fibrillation and type 2 diabetes.

Journal Article Int J Cardiol · August 15, 2019 BACKGROUND: We investigated the use of different antithrombotic therapies at baseline among patients with a history of atrial fibrillation (AF), type 2 diabetes, and established atherosclerotic cardiovascular disease (ASCVD) enrolled in the Trial Evaluatin ... Full text Link to item Cite

Comment on Davis et al. Effects of Severe Hypoglycemia on Cardiovascular Outcomes and Death in the Veterans Affairs Diabetes Trial. Diabetes Care 2019;42:157-163.

Journal Article Diabetes Care · June 2019 Full text Link to item Cite

Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti-hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes.

Journal Article Diabet Med · April 2019 AIMS: In people with metformin-treated diabetes, to evaluate the risk of acute pancreatitis, pancreatic cancer and other diseases of the pancreas post second-line anti-hyperglycaemic agent initiation. METHODS: People with Type 2 diabetes diagnosed after 20 ... Full text Link to item Cite

Authors' reply to "Comment on generalizability of GLP-1 RA CVOTs in US T2D population".

Journal Article Am J Manag Care · April 2019 The authors of the manuscript "Generalizability of Glucagon-Like Peptide-1 Receptor Agonist Cardiovascular Outcome Trials Enrollment Criteria to the US Type 2 Diabetes Population" respond to a letter to the editor. ... Link to item Cite

ASSOCIATIONS BETWEEN BETA-BLOCKER THERAPY AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIABETES AND ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: INSIGHTS FROM THE TECOS STUDY

Conference Journal of the American College of Cardiology · March 2019 Full text Cite

Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials.

Journal Article Circulation · February 12, 2019 Featured Publication BACKGROUND: Modern cardiometabolic clinical trials often include cardiovascular death as a component of a composite primary outcome, requiring central adjudication by a clinical events committee to classify cause of death. However, sometimes the cause of d ... Full text Link to item Cite

Heart Failure With Preserved Ejection Fraction and Diabetes: JACC State-of-the-Art Review.

Journal Article J Am Coll Cardiol · February 12, 2019 Featured Publication Heart failure with preserved ejection fraction (HFpEF) is now the most common form of HF, affecting over 3 million adults in the United States alone. HFpEF is a heterogenous syndrome. One important phenotype may be related to comorbid conditions, including ... Full text Link to item Cite

Progression of glucose-lowering diabetes therapy in TECOS.

Journal Article Endocrinol Diabetes Metab · January 2019 AIMS: TECOS was a randomized, double-blind, placebo-controlled trial assessing the impact of sitagliptin vs. placebo on cardiovascular outcomes when added to usual care in patients with type 2 diabetes. We report the use of concomitant diabetes medications ... Full text Link to item Cite

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study.

Journal Article Clin Kidney J · December 2018 Featured Publication Diabetes is a common cause of chronic kidney disease (CKD), but in aggregate, non-diabetic diseases account for a higher proportion of cases of CKD than diabetes in many parts of the world. Inhibition of the renin-angiotensin system reduces the risk of kid ... Full text Link to item Cite

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.

Journal Article Lancet · October 27, 2018 Featured Publication BACKGROUND: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine t ... Full text Link to item Cite

Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS.

Journal Article Diabetes Obes Metab · October 2018 Featured Publication AIM: To examine sex differences in baseline characteristics and outcomes in patients with type 2 diabetes and atherosclerotic vascular disease. MATERIALS AND METHODS: Cox models were used to analyse the association between sex and outcomes in the Trial Eva ... Full text Link to item Cite

Preventing Heart Failure in Diabetes: Glycemic Targets or Class Effect?

Journal Article JACC Heart Fail · October 2018 Full text Link to item Cite

Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-Rationale, design, and baseline characteristics.

Journal Article Am Heart J · September 2018 Featured Publication BACKGROUND: Albiglutide is a long-acting glucagon-like peptide-1 receptor agonist that improves glycemic control in patients with type 2 diabetes mellitus (T2DM). Harmony Outcomes is a randomized, double-blind, placebo-controlled trial of the effect of alb ... Full text Link to item Cite

The emerging role of novel antihyperglycemic agents in the treatment of heart failure and diabetes: A focus on cardiorenal outcomes.

Journal Article Clin Cardiol · September 2018 Heart failure (HF) and type 2 diabetes mellitus (T2DM) are two global pandemics, affecting over 25 and 420 million people, respectively. The prevalence of comorbid HF and T2DM is rising, and the prognosis remains poor. One central area of overlap of these ... Full text Link to item Cite

Diabetes is Associated with Worse In-Hospital and 30-Day Post-Discharge Morbidity in Patients with Heart Failure with Preserved Ejection Fraction: Findings from the Get With The Guidelines Heart Failure Registry

Conference Journal of Cardiac Failure · August 2018 Full text Cite

LDL-C treatment patterns and associated outcomes in patients with type 2 diabetes and CVD: insights from TECOS

Conference EUROPEAN HEART JOURNAL · August 1, 2018 Link to item Cite

Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).

Journal Article Diabetes Obes Metab · July 2018 AIMS: TECOS, a cardiovascular safety trial (ClinicalTrials.gov identifier: NCT00790205) involving 14 671 patients with type 2 diabetes and cardiovascular disease, demonstrated that sitagliptin was non-inferior to placebo for the primary composite cardiovas ... Full text Link to item Cite

Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population.

Journal Article Am J Manag Care · April 2018 OBJECTIVES: Guidance to industry from the FDA requires studies to evaluate the cardiovascular safety of novel type 2 diabetes (T2D) medications. Although the objectives of such cardiovascular outcomes trials (CVOTs) are similar, differences in features suc ... Link to item Cite

Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials enrollment criteria to the US type 2 diabetes population.

Journal Article Am J Manag Care · April 2018 OBJECTIVES: Cardiovascular outcomes trials (CVOTs) for evaluating the safety of novel antidiabetic agents are required by the FDA. CVOTs vary in their design and inclusion criteria, making it difficult to evaluate their applicability to the general populat ... Link to item Cite

Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials enrollment criteria to the US type 2 diabetes population

Journal Article The American journal of managed care · April 1, 2018 OBJECTIVES: Cardiovascular outcomes trials (CVOTs) for evaluating the safety of novel antidiabetic agents are required by the FDA. CVOTs vary in their design and inclusion criteria, making it difficult to evaluate their applicability to the general populat ... Cite

Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population

Journal Article The American journal of managed care · April 1, 2018 OBJECTIVES: Guidance to industry from the FDA requires studies to evaluate the cardiovascular safety of novel type 2 diabetes (T2D) medications. Although the objectives of such cardiovascular outcomes trials (CVOTs) are similar, differences in features suc ... Cite

Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype.

Journal Article Diabetes Care · March 2018 Featured Publication OBJECTIVE: Severe hypoglycemic events (SHEs) in type 2 diabetes are associated with subsequent cardiovascular (CV) event risk. We examined whether CV events were associated with subsequent SHE risk. RESEARCH DESIGN AND METHODS: Time-dependent associations ... Full text Link to item Cite

Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum.

Journal Article Diabetes Care · January 2018 Featured Publication In December 2008, the U.S. Food and Drug Administration issued guidance to the pharmaceutical industry setting new expectations for the development of antidiabetes drugs for type 2 diabetes. This guidance expanded the scope and cost of research necessary f ... Full text Link to item Cite

Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial.

Journal Article Diabetes Care · December 2017 OBJECTIVE: We evaluated the specific causes of death and their associated risk factors in a contemporary cohort of patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD). RESEARCH DESIGN AND METHODS: We used data from the Trial Ev ... Full text Link to item Cite

The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors.

Journal Article Eur J Heart Fail · November 2017 Heart failure (HF) and type 2 diabetes mellitus (T2DM) are both growing public health concerns contributing to major medical and economic burdens to society. T2DM increases the risk of HF, frequently occurs concomitantly with HF, and worsens the prognosis ... Full text Link to item Cite

Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events: Global Results From the Trial Evaluating Cardiovascular Outcomes With Sitagliptin.

Journal Article Hypertension · November 2017 Systolic blood pressure (SBP) treatment targets for adults with diabetes mellitus remain unclear. SBP levels among 12 275 adults with diabetes mellitus, prior cardiovascular disease, and treated hypertension were evaluated in the TECOS (Trial Evaluating Ca ... Full text Link to item Cite

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.

Journal Article N Engl J Med · September 28, 2017 BACKGROUND: The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown. METHODS: We randomly assigned patients with type 2 diabetes, with or without previous cardiovascular disease, ... Full text Open Access Link to item Cite

Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin).

Journal Article Circulation · September 26, 2017 BACKGROUND: Intensive risk factor modification significantly improves outcomes for patients with diabetes mellitus and cardiovascular disease. However, the degree to which secondary prevention treatment goals are achieved in international clinical practice ... Full text Link to item Cite

Cardiovascular Outcome Trial Update in Diabetes: New Evidence, Remaining Questions.

Journal Article Curr Diab Rep · September 2017 PURPOSE OF REVIEW: Seven trials of new agents to treat type 2 diabetes (T2DM) have been performed to assess cardiovascular (CV) safety. A significant amount of information regarding the effects of drugs in three classes is available, with new data from mul ... Full text Link to item Cite

Resource use and UK-perspective costs in patients with type 2 diabetes during the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)

Conference DIABETOLOGIA · September 1, 2017 Link to item Cite

Time to insulin in the Trial Evaluating Cardiovascular Outomes with Sitagliptin (TECOS)

Conference DIABETOLOGIA · September 1, 2017 Link to item Cite

Risk of pancreatic diseases by second-line anti diabetes drug class: real world based evidence

Conference DIABETOLOGIA · September 1, 2017 Link to item Cite

The association between obesity, diabetes control, and cardiovascular outcomes: insights from the TECOS trial

Conference EUROPEAN HEART JOURNAL · August 1, 2017 Link to item Cite

From Bench to Bedside: Converting Placebo Research into Belief Activation.

Journal Article J Altern Complement Med · August 2017 Research on the placebo effect contains important elements that can be harnessed to improve clinical care. This paper proposes a new term, "Belief Activation," to describe the deliberate use of placebo effect tools by both patients and clinicians to cataly ... Full text Link to item Cite

Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).

Journal Article Diabetes Care · April 2017 OBJECTIVE: Limited data exist regarding safety and efficacy of antihyperglycemic drugs in older patients with type 2 diabetes. The Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) was a randomized, double-blind, placebo-controlled trial as ... Full text Link to item Cite

Assessing electronic health record phenotypes against gold-standard diagnostic criteria for diabetes mellitus.

Journal Article J Am Med Inform Assoc · April 1, 2017 OBJECTIVE: We assessed the sensitivity and specificity of 8 electronic health record (EHR)-based phenotypes for diabetes mellitus against gold-standard American Diabetes Association (ADA) diagnostic criteria via chart review by clinical experts. MATERIALS ... Full text Link to item Cite

Pancreatic Safety of Sitagliptin in the TECOS Study.

Journal Article Diabetes Care · February 2017 OBJECTIVE: We evaluated the incidence of acute pancreatitis and pancreatic cancer in patients with type 2 diabetes and cardiovascular disease who were treated with sitagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4i). RESEARCH DESIGN AND METHODS: In th ... Full text Link to item Cite

SYNTAX Score and Long-Term Outcomes: The BARI-2D Trial.

Journal Article J Am Coll Cardiol · January 31, 2017 BACKGROUND: The extent of coronary disease affects clinical outcomes and may predict the effectiveness of coronary revascularization with either coronary artery bypass graft (CABG) surgery or percutaneous coronary intervention (PCI). The SYNTAX (Synergy Be ... Full text Link to item Cite

Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial.

Journal Article Diabetes Obes Metab · January 2017 AIM: To examine fracture incidence among participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). RESEARCH DESIGN AND METHODS: We used data from 14 671 participants in the TECOS study who were randomized double-blind to sitagl ... Full text Link to item Cite

Management of newly treated diabetes in Medicare beneficiaries with and without heart failure.

Journal Article Clin Cardiol · January 2017 BACKGROUND: Several diabetes mellitus (DM) therapies are associated with worse heart failure (HF) outcomes, yet limited data exist characterizing routine DM management based on HF status. HYPOTHESIS: DM medications prescribed for patients with HF will diff ... Full text Link to item Cite

International Variation in Management and Clinical Outcome of Patients With Type 2 Diabetes and Heart Failure: Insights From TECOS

Conference CIRCULATION · 2017 Cite

Underuse of Oral Anticoagulation, High Use of Aspirin and Worse Clinical Outcomes in Patients With Type 2 Diabetes and Atrial Fibrillation: Insights From the TECOS Trial

Conference CIRCULATION · 2017 Cite

Current cardiovascular outcomes trials in type 2 diabetes: Perspectives and insight.

Journal Article Nutr Metab Cardiovasc Dis · September 2016 AIMS: The increased risk of cardiovascular disease in patients with type 2 diabetes has been known for many years. However, until recently the cardiovascular (CV) impact of glucose lowering strategies has been inadequately understood. Major clinical trials ... Full text Link to item Cite

Sex differences in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)

Conference DIABETOLOGIA · August 1, 2016 Link to item Cite

Sitagliptin and risk of fractures in type 2 diabetes: results from the TECOS trial

Conference DIABETOLOGIA · August 1, 2016 Link to item Cite

Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.

Journal Article JAMA Cardiol · May 1, 2016 IMPORTANCE: Previous trial results have suggested that dipeptidyl peptidase 4 inhibitor (DPP4i) use might increase heart failure (HF) risk in type 2 diabetes mellitus (T2DM). The DPP4i sitagliptin has been shown to be noninferior to placebo with regard to ... Full text Link to item Cite

Recent Clinical Trials in Osteoporosis: A Firm Foundation or Falling Short?

Journal Article PLoS One · 2016 The global burden of osteoporotic fractures is associated with significant morbidity, mortality, and healthcare costs. We examined the ClinicalTrials.gov database to determine whether recently registered clinical trials addressed prevention and treatment i ... Full text Open Access Link to item Cite

Systolic Blood Pressure Control Among Individuals With Type 2 Diabetes: A Comparative Effectiveness Analysis of Three Interventions.

Journal Article Am J Hypertens · August 2015 BACKGROUND: The relative effectiveness of 3 approaches to blood pressure control-(i) an intensive lifestyle intervention (ILI) focused on weight loss, (ii) frequent goal-based monitoring of blood pressure with pharmacological management, and (iii) educatio ... Full text Link to item Cite

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.

Journal Article N Engl J Med · July 16, 2015 Featured Publication BACKGROUND: Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease. METHODS: In this randomized, double-blind st ... Full text Link to item Cite

Update in endocrinology: evidence published in 2014.

Journal Article Ann Intern Med · May 5, 2015 Featured Publication Full text Link to item Cite

Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).

Journal Article Diabetes Obes Metab · April 2015 AIMS: To report baseline characteristics and cardiovascular (CV) risk management by region, age, sex and CV event type for 14 724 participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS), a randomized, double-blind, placebo-con ... Full text Link to item Cite

Long-term clinical and angiographic outcomes in patients with diabetes undergoing coronary artery bypass graft surgery: results from the Project of Ex-vivo Vein Graft Engineering via Transfection IV trial.

Journal Article Am Heart J · January 2015 BACKGROUND: There is limited information about the association between diabetes, its treatment, and long-term angiographic and clinical outcomes in patients undergoing coronary artery bypass graft surgery (CABG). We evaluated the association of diabetes an ... Full text Link to item Cite

Sex, Prescribing Practices and Guideline Recommended, Blood Pressure, and LDL Cholesterol Targets at Baseline in the BARI 2D Trial.

Journal Article Int J Endocrinol · 2015 Background. Research has shown less aggressive treatment and poorer control of cardiovascular disease (CVD) risk factors in women than men. Methods. We analyzed sex differences in pharmacotherapy strategies and attainment of goals for hemoglobin A1c (HbA1c ... Full text Link to item Cite

Understanding the type 2 diabetes mellitus and cardiovascular disease risk paradox.

Journal Article Postgrad Med · May 2014 Patients with diabetes have approximately a 2-fold increase in the risk for coronary heart disease, stroke, and death from vascular causes compared with patients who do not have diabetes. Interventions targeted at modifiable risk factors, such as smoking c ... Full text Link to item Cite

Determinants of successful glycemic control among participants in the BARI 2D trial: a post-hoc analysis.

Journal Article J Diabetes Complications · 2014 Featured Publication OBJECTIVE: The BARI 2D trial compared insulin provision (IP) versus insulin sensitization (IS) for the primary outcome of total mortality in participants with T2DM and cardiovascular disease (CVD). In this analysis we examine baseline characteristics that ... Full text Link to item Cite

Lower levels of circulating progenitor cells are associated with low physical function and performance in elderly men with impaired glucose tolerance: a pilot substudy from the VA Enhanced Fitness trial.

Journal Article J Gerontol A Biol Sci Med Sci · December 2013 BACKGROUND: Aging is marked by a decline in physical function. Although the biological underpinnings for this remain unclear, loss of regenerative capacity has been proposed as one cause of the loss of physical function that occurs over time. The quantity ... Full text Link to item Cite

Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.

Journal Article Am Heart J · December 2013 Featured Publication Sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, lowers blood glucose when administered as monotherapy or in combination with other antihyperglycemic agents. TECOS will evaluate the effects of adding sitagliptin to usual diabetes care on cardiovascul ... Full text Link to item Cite

Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort.

Journal Article Diabetes Care · October 2013 OBJECTIVE: The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial demonstrated similar long-term clinical effectiveness of insulin-sensitizing (IS) versus insulin-providing (IP) treatments for type 2 diabetes on cardiovascular ou ... Full text Link to item Cite

Diabetes trials: is an ounce of prevention enough?

Journal Article Expert Rev Endocrinol Metab · September 2013 Full text Link to item Cite

Are current clinical trials in diabetes addressing important issues in diabetes care?

Journal Article Diabetologia · June 2013 Featured Publication AIMS/HYPOTHESIS: Clinical trials assessing interventions for treating and preventing diabetes mellitus and its complications are needed to inform evidence-based practice. To examine whether current studies adequately address these needs, we conducted a des ... Full text Link to item Cite

Depletion of circulating progenitor cells precedes overt diabetes: a substudy from the VA enhanced fitness trial.

Journal Article J Diabetes Complications · 2013 BACKGROUND: One theory of aging and disease development is that chronic injury (pathology) results in activation of regenerative processes and initial repair, with overt disease arising only after exhaustion of reparative capability leads to inadequate rep ... Full text Link to item Cite

State of diabetes-related trials in the clinicaltrials.gov dataset

Journal Article DIABETOLOGIA · October 1, 2012 Link to item Cite

Enhanced fitness: a randomized controlled trial of the effects of home-based physical activity counseling on glycemic control in older adults with prediabetes mellitus.

Journal Article J Am Geriatr Soc · September 2012 Featured Publication OBJECTIVES: To determine whether a home-based multicomponent physical activity counseling (PAC) intervention is effective in reducing glycemic measures in older outpatients with prediabetes mellitus. DESIGN: Controlled clinical trial. SETTING: Primary care ... Full text Open Access Link to item Cite

Intensive glycemic control is not associated with fractures or falls in the ACCORD randomized trial.

Journal Article Diabetes Care · July 2012 Featured Publication OBJECTIVE: Older adults with type 2 diabetes are at high risk of fractures and falls, but the effect of glycemic control on these outcomes is unknown. To determine the effect of intensive versus standard glycemic control, we assessed fractures and falls as ... Full text Link to item Cite

The dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safety.

Journal Article Postgrad Med · July 2012 Featured Publication The dipeptidyl peptidase-4 (DPP-4) inhibitors are a relatively new class of oral antidiabetic agents that improve glycemic control in patients with type 2 diabetes mellitus. These agents differ in structure, but all act by inhibiting the DPP-4 enzyme. Dipe ... Full text Link to item Cite

Is silent myocardial infarction more common in women with type 2 diabetes than in men?

Journal Article J Diabetes Complications · 2012 OBJECTIVE: Our aim was to determine if silent myocardial infarction (MI) is more common in women with type 2 diabetes than in men. Our secondary aim was to examine the relationships between silent MI and risk factors for cardiovascular disease. RESEARCH DE ... Full text Link to item Cite

Glycemic management in diabetes and the associated cardiovascular risk: are we helping or hurting our patients?

Journal Article Circ J · 2012 Diabetes, which is a metabolic disorder with multiple comorbidities, increases the risk of cardiovascular disease. Although it was once assumed that controlling plasma glucose levels would reduce diabetes-related morbidity and mortality, recent trials have ... Full text Link to item Cite

Lessons learned when innovations go awry: a baseline description of a behavioral trial-the Enhancing Fitness in Older Overweight Veterans with Impaired Fasting Glucose study.

Journal Article Transl Behav Med · November 2011 Individuals diagnosed with impaired glucose tolerance (i.e., prediabetes) are at increased risk for developing diabetes. We proposed a clinical trial with a novel adaptive randomization designed to examine the impact of a home-based physical activity (PA) ... Full text Open Access Link to item Cite

Successful transitions from MDI therapy to sensor-augmented pump therapy in the STAR 3 study: system settings and behaviours

Conference DIABETOLOGIA · September 1, 2011 Featured Publication Link to item Cite

Baseline predictors of A1C reduction in adults using sensor-augmented pump therapy or multiple daily injection therapy: the STAR 3 experience.

Journal Article Diabetes Technol Ther · June 2011 Featured Publication BACKGROUND: Baseline characteristics from the adult cohort of a randomized controlled trial comparing sensor-augmented pump (SAP) and multiple daily injection (MDI) therapy were analyzed for significant relationships with -0.5% A1C change at 1 year of ther ... Full text Link to item Cite

First reported case of unilateral Graves' disease in the left lobe of a bilobar thyroid gland.

Journal Article Thyroid · June 2011 BACKGROUND: Unilateral Graves' disease is a rare disease variant that can occur in a bilobar thyroid gland. We report the first documented case of unilateral Graves' disease in the left lobe of a bilobar thyroid gland and review the pertinent literature. P ... Full text Link to item Cite

Effects of pregabalin on heart rate variability in patients with painful diabetic neuropathy.

Journal Article J Clin Psychopharmacol · April 2011 UNLABELLED: Many studies have demonstrated that low heart rate variability (HRV) is a risk for high mortality and morbidity in patients with cardiovascular diseases. The primary purpose of the study was to evaluate whether pregabalin improves HRV in patien ... Full text Link to item Cite

Clinical utility of fixed combinations of sitagliptin-metformin in treatment of type 2 diabetes.

Journal Article Diabetes Metab Syndr Obes · October 27, 2010 Adequate glycemic control in type 2 diabetes remains a difficult but achievable goal. The development of new classes of glucose-lowering medications, including in particular the incretin-based therapies, provides an opportunity to utilize combinations of m ... Full text Link to item Cite

Glycaemia management of minority participants in ACCORD

Conference DIABETOLOGIA · September 1, 2010 Link to item Cite

Glucose control in adults during a 1-year randomised controlled trial comparing sensor-augmented pump therapy and multiple daily injection therapy: STAR 3 study

Conference DIABETOLOGIA · September 1, 2010 Link to item Cite

Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy.

Journal Article Drug Healthc Patient Saf · 2010 Although glycemic control is an important and effective way to prevent and minimize the worsening of diabetes-related complications, type 2 diabetes is a progressive disease which often proves difficult to manage. Most affected patients will eventually req ... Full text Link to item Cite

Present and Prospective Pharmacotherapy for the Management of Patients with Type 2 Diabetes.

Journal Article Clinical medicine. Therapeutics · August 2009 Diabetes Mellitus is a chronic condition prevalent worldwide. Type 2 diabetes is the most common form of diabetes, comprising 90% to 95% of all cases. Over the last few decades, the importance of glycemic control and its impact on prevention of diabetes-re ... Cite

Relation of severe coronary artery narrowing to insulin or thiazolidinedione use in patients with type 2 diabetes mellitus (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes Study).

Journal Article Am J Cardiol · July 1, 2009 Patients with diabetes continue to die of coronary artery disease (CAD) at rates 2 to 4 times higher than patients without diabetes, despite advances in treatment of cardiovascular disease. The role of glycemic control therapies, independent of their gluco ... Full text Link to item Cite

Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort.

Journal Article J Peripher Nerv Syst · March 2009 We evaluated the associations between glycemic therapies and prevalence of diabetic peripheral neuropathy (DPN) at baseline among participants in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial on medical and revasculariza ... Full text Link to item Cite

Effects of intensive glucose lowering in type 2 diabetes.

Journal Article N Engl J Med · June 12, 2008 BACKGROUND: Epidemiologic studies have shown a relationship between glycated hemoglobin levels and cardiovascular events in patients with type 2 diabetes. We investigated whether intensive therapy to target normal glycated hemoglobin levels would reduce ca ... Full text Link to item Cite

New combination treatments in the management of diabetes: focus on sitagliptin-metformin.

Journal Article Vasc Health Risk Manag · 2008 Type 2 diabetes mellitus is an increasingly prevalent condition worldwide. The complications of this disease are known to significantly increase the morbidity and mortality of those affected, resulting in substantial direct and indirect costs. Although goo ... Full text Link to item Cite

Exenatide and rimonabant: new treatments that may be useful in the management of diabetes and obesity.

Journal Article Curr Diab Rep · October 2007 Diabetes mellitus and obesity have become increasingly prevalent problems worldwide. Unfortunately, with traditionally prescribed glucose-lowering medications most individuals with diagnosed diabetes do not achieve and maintain adequate glycemic control ov ... Full text Link to item Cite

Update on type 2 diabetes mellitus: understanding changes in the diabetes treatment paradigm.

Journal Article Int J Clin Pract Suppl · August 2007 Type 2 diabetes mellitus, which is increasingly prevalent in the United States and responsible for the bulk of diabetes-related healthcare costs, has not been adequately managed over the long term with the most commonly prescribed oral hypoglycaemic medica ... Full text Link to item Cite

Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: Design and methods

Journal Article American Journal of Cardiology · June 18, 2007 Featured Publication Most patients with type 2 diabetes mellitus develop cardiovascular disease (CVD), with substantial loss of life expectancy. Nonfatal CVD contributes greatly to excess healthcare costs and decreased quality of life in patients with diabetes. The current epi ... Full text Cite

Disorders of monosaccharide metabolism

Chapter · January 1, 2007 Humans are largely dependent upon glucose-and to a lesser extent, the monosaccharides galactose and fructose-to provide fuel for cellular metabolism. Levels of blood glucose are maintained fairly precisely through a balance of dietary intake, breakdown of ... Cite

Diabetes Mellitus and Cardiac Rehabilitation in Clinical Practice

Chapter · 2007 Full text Cite

Are sulfonylureas passé?

Journal Article Curr Diab Rep · November 2006 Sulfonylureas and similarly acting rapid insulin secretagogues have long been available to manage type 2 diabetes. These agents have a well understood mechanism of action and are in large part well tolerated. However, sulfonylurea therapy is unlikely to su ... Full text Link to item Cite

How bone density testing influenced osteoporosis treatment in a community hospital.

Journal Article N C Med J · 2000 Link to item Cite